The main priorities to monitor for PWD were burden of self-management, symptom distress related to multiple side effects including gastro-intestinal symptoms, injection issues and hypoglycemia with the latter two issues being specific for insulin-treated PWD. Here, INS is linked to Hypoglycemia.